229 related articles for article (PubMed ID: 16594577)
61. Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release.
Krämer AL; Riederer A; Fracassi F; Boretti FS; Sieber-Ruckstuhl NS; Lutz TA; Contiero B; Zini E; Reusch CE
J Vet Intern Med; 2020 Nov; 34(6):2287-2295. PubMed ID: 33001499
[TBL] [Abstract][Full Text] [Related]
62. Insulin glargine treatment of a ferret with diabetes mellitus.
Hess L
J Am Vet Med Assoc; 2012 Dec; 241(11):1490-4. PubMed ID: 23176242
[TBL] [Abstract][Full Text] [Related]
63. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.
Ocheltree SM; Hompesch M; Wondmagegnehu ET; Morrow L; Win K; Jacober SJ
Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081
[TBL] [Abstract][Full Text] [Related]
64. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
Blair HA; Keating GM
Drugs; 2016 Mar; 76(3):363-74. PubMed ID: 26821280
[TBL] [Abstract][Full Text] [Related]
65. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
66. Evaluation of IGF-1 levels in cats with transient and permanent diabetes mellitus.
Alt N; Kley S; Tschuor F; Zapf J; Reusch CE
Res Vet Sci; 2007 Dec; 83(3):331-5. PubMed ID: 17367830
[TBL] [Abstract][Full Text] [Related]
67. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
[TBL] [Abstract][Full Text] [Related]
68. Rebound hyperglycemia following overdosing of insulin in cats with diabetes mellitus.
McMillan FD; Feldman EC
J Am Vet Med Assoc; 1986 Jun; 188(12):1426-31. PubMed ID: 3528096
[TBL] [Abstract][Full Text] [Related]
69. The evolution of insulin glargine and its continuing contribution to diabetes care.
Hilgenfeld R; Seipke G; Berchtold H; Owens DR
Drugs; 2014 Jun; 74(8):911-27. PubMed ID: 24866023
[TBL] [Abstract][Full Text] [Related]
70. Feline comorbidities: Pathophysiology and management of the obese diabetic cat.
Clark M; Hoenig M
J Feline Med Surg; 2021 Jul; 23(7):639-648. PubMed ID: 34167340
[TBL] [Abstract][Full Text] [Related]
71. Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus.
Hadd MJ; Bienhoff SE; Little SE; Geller S; Ogne-Stevenson J; Dupree TJ; Scott-Moncrieff JC
J Vet Intern Med; 2023; 37(3):915-924. PubMed ID: 37148170
[TBL] [Abstract][Full Text] [Related]
72. Intensive intravenous infusion of insulin in diabetic cats.
Hafner M; Dietiker-Moretti S; Kaufmann K; Mueller C; Lutz TA; Reusch CE; Zini E
J Vet Intern Med; 2014; 28(6):1753-9. PubMed ID: 25312554
[TBL] [Abstract][Full Text] [Related]
73. Evaluation of insulin-like growth factor-1, total thyroxine, feline pancreas-specific lipase and urinary corticoid-to-creatinine ratio in cats with diabetes mellitus in Switzerland and the Netherlands.
Schaefer S; Kooistra HS; Riond B; Suchodolski JS; Steiner JM; Prins M; Zini E; Reusch CE
J Feline Med Surg; 2017 Aug; 19(8):888-896. PubMed ID: 27578200
[TBL] [Abstract][Full Text] [Related]
74. Intermediate-acting insulin preparations: NPH and lente.
Deckert T
Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205
[TBL] [Abstract][Full Text] [Related]
75. Clinical usefulness of fructosamine measurements in diagnosing and monitoring feline diabetes mellitus.
Thoresen SI; Bredal WP
J Small Anim Pract; 1996 Feb; 37(2):64-8. PubMed ID: 8656595
[TBL] [Abstract][Full Text] [Related]
76. Treatment of an acromegalic cat with the dopamine agonist L-deprenyl.
Abraham LA; Helmond SE; Mitten RW; Charles JA; Holloway SA
Aust Vet J; 2002 Aug; 80(8):479-83. PubMed ID: 12224616
[TBL] [Abstract][Full Text] [Related]
77. Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus.
Benedict SL; Mahony OM; McKee TS; Bergman PJ
Can J Vet Res; 2022 Jan; 86(1):52-58. PubMed ID: 34975223
[TBL] [Abstract][Full Text] [Related]
78. Insulin glargine controversy: a tribute to the editorial team at Diabetologia.
Butler PC
Diabetes; 2009 Nov; 58(11):2427-8. PubMed ID: 19875618
[No Abstract] [Full Text] [Related]
79. Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues.
Simon D
Diabetologia; 2010 Jan; 53(1):204-5. PubMed ID: 19859691
[No Abstract] [Full Text] [Related]
80. Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats.
Saini NK; Wasik B; Pires J; Leale DM; Quach N; Culp WTN; Samms RJ; Johnson AE; Owens JG; Gilor C
Domest Anim Endocrinol; 2021 Apr; 75():106595. PubMed ID: 33307335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
